Journal of geriatric oncology最新文献

{"title":"Patient education for older adults with cancer and their caregivers: A scoping review.","authors":"Lu Lin, Schroder Sattar, Ivan Steenstra, Nai-Wen Ku, Swatika Anand, Harriet Ho, Christina Oleynikov, Kristen Haase, Isabella Celik, Sara Mirzaei, Maryjo Antonio, Indrani Paul, Silmi Hirji, Morayo Aladejana, Ryan McNally, Janet Papadakos, Rouhi Fazelzad, Fay Bennie, Shabbir Alibhai, Martine Puts","doi":"10.1016/j.jgo.2026.104656","DOIUrl":"https://doi.org/10.1016/j.jgo.2026.104656","url":null,"abstract":"<p><strong>Introduction: </strong>Patient education is essential for older adults with cancer and their caregivers to support understanding of diagnosis and treatment. However, the evidence describing patient education interventions has not been comprehensively mapped. Our objective was to characterize the features, delivery approaches, and outcomes of patient education interventions developed for older adults with cancer and/or their caregivers across any study design, and to identify gaps in the evidence.</p><p><strong>Materials and methods: </strong>A scoping review was conducted using the Arksey and O'Malley framework and reported according to the PRISMA-ScR guideline. MEDLINE, EMBASE, EMCARE, CENTRAL, PsycINFO, and Scopus were searched on January 23, 2025. Studies published from 2000 onward were included if they evaluated healthcare professional-delivered patient education.</p><p><strong>Results: </strong>From 26,898 records screened, 93 studies met inclusion criteria. Most interventions were delivered pre-treatment (n = 63), with surgery the most common context (n = 31). Common aims included side-effect prevention (n = 32) and supporting treatment decision-making (n = 26). Caregiver involvement was limited. Outcomes were clustered into 20 domains. Frequent reported domains were satisfaction/acceptability (52 occurrences) and knowledge/understanding (46 occurrences), while caregiver outcomes and clinical endpoints were rarely assessed.</p><p><strong>Discussion: </strong>Patient education interventions generally improved knowledge and satisfaction, but evidence for clinical or system-level impacts remains limited. Key gaps include minimal integration of geriatric assessment, limited adaptation for cognitive impairment, sparse caregiver-specific outcomes, and inconsistent reporting of unintended effects. Future research should better integrate caregiver needs and geriatric principles into patient education design.</p>","PeriodicalId":15943,"journal":{"name":"Journal of geriatric oncology","volume":"18 2","pages":"104656"},"PeriodicalIF":2.9,"publicationDate":"2026-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149228063","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Frailty in routine oncology care: From estimation and prognostication to action.","authors":"Daniel Sibley, Shabbir M H Alibhai","doi":"10.1016/j.jgo.2026.104153","DOIUrl":"https://doi.org/10.1016/j.jgo.2026.104153","url":null,"abstract":"","PeriodicalId":15943,"journal":{"name":"Journal of geriatric oncology","volume":" ","pages":"104153"},"PeriodicalIF":2.9,"publicationDate":"2026-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149061613","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Frailty and mortality in patients with cancer: A systematic review and meta-analysis of 191 observational studies.","authors":"Cristine M Brum, Anderson Rech, Régis Radaelli, Maria Petropoulou, Râmi A P Lorandi, Catherine F Maziero, Maria Eduarda B Bazzo, Bernardo T Rachele, Vinícius R Migliavacca, Janaína Brollo, Maximiliano C Kneubil, Claudio Pescador Júnior, Francesco Bettariga, Carin W Gallon, Pedro Lopez","doi":"10.1016/j.jgo.2026.103418","DOIUrl":"https://doi.org/10.1016/j.jgo.2026.103418","url":null,"abstract":"<p><strong>Introduction: </strong>Frailty is increasingly recognized as a marker of vulnerability in patients with cancer yet not performed in routine oncology care due to practical barriers, including lack of knowledge and limited human, temporal and spatial resources. Additionally, a comprehensive pan-cancer synthesis across all validated instruments is currently lacking. Consequently, the magnitude and consistency of the association across different demographic, clinical, cancer (types, disease stages, treatment modalities), and frailty instruments characteristics have not been comprehensively quantified. Therefore, we aimed to examine the association between frailty and all-cause and cancer-specific mortality in patients with cancer and to explore demographic, clinical, and treatment-related factors that may affect this relationship.</p><p><strong>Materials and methods: </strong>In this systematic review, PubMed, EMBASE, CINAHL, Web of Science, LILACS, and SciELO were searched from inception to August 2025. Observational studies assessing the association between frailty and mortality in adults (≥18 years) with cancer were included. Screening was performed independently by multiple reviewers. The methodological quality was evaluated using the Newcastle-Ottawa Quality Assessment Scale (NOS) for cohort studies. Random-effects meta-analyses, subgroup and meta-regression analyses were undertaken.</p><p><strong>Results: </strong>A total of 191 studies comprising over 626,975 patients (median age, 72.0 years; 40.0% male) were included. Regarding the quality assessment, 160 studies (83.8%) scored 9 points in the Newcastle-Ottawa Scale, with scores ranging from 7 to 9. Frailty was independently associated with higher all-cause mortality (n = 162; adjusted HR, 1.98; 95% CI, 1.85-2.09), with consistent findings after sensitivity analyses. Frailty was also associated with higher cancer-specific mortality (n = 18; adjusted HR, 1.84; 95% CI, 1.58-2.15). Subgroup and meta-regression analyses did not identify significant association of age, sex, body mass index, cancer stage, performance status, or treatment modalities with frailty and mortality.</p><p><strong>Discussion: </strong>Frailty is a consistent and independent prognostic factor for mortality in patients with cancer. These findings support the integration of frailty assessment into routine oncology practice to improve risk stratification and inform more individualised treatment decision-making beyond traditional clinical indicators.</p>","PeriodicalId":15943,"journal":{"name":"Journal of geriatric oncology","volume":" ","pages":"103418"},"PeriodicalIF":2.9,"publicationDate":"2026-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148955310","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comment on \"Transcutaneous auricular vagus nerve stimulation for prevention of postoperative cognitive dysfunction in older adults with gastrointestinal tumors: A randomized controlled trial\".","authors":"Barbara Deschler-Baier","doi":"10.1016/j.jgo.2026.103050","DOIUrl":"https://doi.org/10.1016/j.jgo.2026.103050","url":null,"abstract":"","PeriodicalId":15943,"journal":{"name":"Journal of geriatric oncology","volume":" ","pages":"103050"},"PeriodicalIF":2.9,"publicationDate":"2026-07-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148396691","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patient-reported outcomes in BRUIN CLL-321: A randomized phase 3 trial comparing pirtobrutinib to investigators choice of idelalisib plus rituximab or bendamustine plus rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma in the post-cBTKi setting","authors":"Paolo Ghia,&nbsp;Davide Rossi,&nbsp;Emmanuelle Ferrant,&nbsp;Fátima de la Cruz Vicente,&nbsp;Dai Maruyama,&nbsp;Versha Banerji,&nbsp;Patrick Cobb,&nbsp;Swathi Namburi,&nbsp;Richard Greil,&nbsp;Jeff P. Sharman,&nbsp;Lisa M. Hess,&nbsp;Nalin Payakachat,&nbsp;Naleen Raj Bhandari,&nbsp;Amy S. Ruppert,&nbsp;Denise Wang,&nbsp;Paolo Abada,&nbsp;Angély Loubert,&nbsp;Kristin Creel,&nbsp;Carol Qiao,&nbsp;Yimei Han,&nbsp;Paul M. Barr","doi":"10.1016/j.jgo.2026.103024","DOIUrl":"10.1016/j.jgo.2026.103024","url":null,"abstract":"<div><h3>Introdcution</h3><div>The phase 3, randomized trial BRUIN CLL-321 assessed the safety and efficacy of pirtobrutinib versus investigators choice of idelalisib plus rituximab (IdelaR) or bendamustine plus rituximab (BR) in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) previously treated with a covalent BTK inhibitor. BRUIN CLL-321 showed significantly improved progression-free survival with pirtobrutinib compared to IdealR/BR. We report secondary endpoints including time to worsening (TTW) of CLL/SLL-related symptoms and physical function (PF).</div></div><div><h3>Materials and Methods</h3><div>Patients with relapsed/refractory CLL/SLL who received at least one prior cBTKi were enrolled in BRUIN CLL-321. Exploratory endpoints were evaluated using mixed models for repeated measures analysis for within- and between-group differences. Patient-reported outcomes (PROs) were collected every 4 weeks during study treatment through week 25 on both arms. TTW was evaluated using log rank test and Cox proportional hazards model. The statistical testing of PRO endpoints was not type-1 error controlled and thus descriptive in nature.</div></div><div><h3>Results</h3><div>A total of 119 patients were randomized to each treatment arm (<em>N</em> = 238). Median TTW in CLL/SLL-related symptoms (HR,0.972 [95%CI, 0.461–2.048; <em>p</em> = 0.89) and PF (HR, 0.590 [95%CI, 0.262–1.326]; <em>p</em> = 0.33) was not reached in either treatment arm. Pirtobrutinib demonstrated clinically meaningful improvements from baseline in CLL/SLL-related symptoms, PF, and fatigue at all post-baseline assessments (least squares [LS] means change ranged from −7.0 to −11.8, +5.4 to +8.9, and − 7.0 to −12.7, respectively). Comparing between groups, CLL/SLL-related symptoms were clinically meaningfully lower in the pirtobrutinib group versus IdelaR/BR at Week 9 (LSM_d,-7.3 [standard error (SE), 2.2]), Week 13 (LSM_d,-6.7 [SE, 2.3]), Week 17 (LSM_d,-4.6 [SE, 2.3]), and Week 21 (LSM_d,-7.0 [SE, 2.3]). Patients receiving pirtobrutinib reported better PF versus IdelaR/BR at Weeks 13 (LSM_d,5.6 [SE, 2.4]) and 21 (LSM_d,5.9 [SE, 2.5]). Patients receiving pirtobrutinib also reported clinically meaningful lower fatigue versus IdelaR/BR at Week 9 (LSM_d,-9.0 [SE, 2.9]), Week 13 (LSM_d,-6.7 [SE, 3.0]), and Week 21 (LSM_d,-6.9 [SE, 3.1]).</div></div><div><h3>Discussion</h3><div>These analyses demonstrate clinically meaningful improvements for pirtobrutinib at all post-baseline assessments for CLL/SLL-related symptoms, PF, and fatigue. Consistent benefit was seen in CLL/SLL-related symptoms, PF, and fatigue with pirtobrutinib versus IdelaR/BR, with most PRO assessments meeting clinically meaningful differences between groups.</div></div>","PeriodicalId":15943,"journal":{"name":"Journal of geriatric oncology","volume":"17 6","pages":"Article 103024"},"PeriodicalIF":2.9,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148271888","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Broadening perspectives on interpreting “overtreatment” and “undertreatment” in older patients with high-risk breast cancer","authors":"Ilyas Dar,&nbsp;Renata Neciunaite,&nbsp;Louis J. Koizia,&nbsp;Benjamin H.L. Harris","doi":"10.1016/j.jgo.2026.102975","DOIUrl":"10.1016/j.jgo.2026.102975","url":null,"abstract":"","PeriodicalId":15943,"journal":{"name":"Journal of geriatric oncology","volume":"17 6","pages":"Article 102975"},"PeriodicalIF":2.9,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148150065","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of immunotherapy in older adults with triple-negative breast cancer: A systematic review","authors":"Carrie Sha,&nbsp;Marie Liu,&nbsp;Ashley Schreier,&nbsp;Roberta Zappasodi,&nbsp;Johanna Goldberg,&nbsp;Iris Zhi","doi":"10.1016/j.jgo.2026.103027","DOIUrl":"10.1016/j.jgo.2026.103027","url":null,"abstract":"<div><h3>Introduction</h3><div>Immune checkpoint inhibitors (ICI) have transformed the treatment landscape for triple-negative breast cancer (TNBC), but their efficacy in older adults remains unclear. The objective of this systematic review is to evaluate the efficacy of ICI in patients with TNBC aged ≥65 years.</div></div><div><h3>Materials and methods</h3><div>We conducted a systematic review of randomized controlled trials (RCTs) between January 2013 and September 2023 using searches of Medline, Embase, the Cochrane Central Register of Controlled Trials, <span><span>ClinicalTrials.gov</span><svg><path></path></svg></span>, and the WHO International Clinical Trials Registry Platform.</div></div><div><h3>Results</h3><div>Eighteen full-text articles representing 11 unique RCTs were identified. Only four RCTs reported efficacy outcomes for patients ≥65 years: KEYNOTE 355, KEYNOTE 522, IMpassion130, and IMpassion131. Across these trials, 602 of 3215 patients (18.7%) were 65 and older. The overall risk of bias was low to intermediate, but heterogeneity in trial design and endpoints precluded meta-analysis. Pembrolizumab, the only FDA-approved ICI in TNBC, showed a nonsignificant trend toward improved pathological complete response and event-free survival among older adults with early-stage TNBC (KEYNOTE-522). In the metastatic setting, pembrolizumab may improve overall survival in older patients with PD-L1 combined positive score ≥ 10 (KEYNOTE-355). All studies enrolled few older patients, and none prespecified age-stratified analyses.</div></div><div><h3>Discussion</h3><div>These findings highlight a major evidence gap and underscore the need for further research evaluating ICI outcomes in older adults with TNBC.</div></div>","PeriodicalId":15943,"journal":{"name":"Journal of geriatric oncology","volume":"17 6","pages":"Article 103027"},"PeriodicalIF":2.9,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148258228","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Author’s response to Letter to the Editor “causes of death in older patients with high-risk breast cancer: What are the most significant contributors?”","authors":"Hong Li,&nbsp;Lovedeep Gondara,&nbsp;Caroline Speers,&nbsp;Caroline Lohrisch,&nbsp;Alan Nichol,&nbsp;Richard Musoke,&nbsp;Caroline Mariano","doi":"10.1016/j.jgo.2026.102974","DOIUrl":"10.1016/j.jgo.2026.102974","url":null,"abstract":"","PeriodicalId":15943,"journal":{"name":"Journal of geriatric oncology","volume":"17 6","pages":"Article 102974"},"PeriodicalIF":2.9,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147716776","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"“An opportunity to spend time with each other”: The importance of mealtimes for carepartners of older adults with acute myeloid leukemia and myelodysplastic syndromes","authors":"Victoria Crowder,&nbsp;Youngmin Cho,&nbsp;Chiao-Hsin Teng,&nbsp;Danielle Anderson,&nbsp;Melissa Batchelor,&nbsp;Anna Beeber,&nbsp;Lorinda A. Coombs,&nbsp;Daniel Richardson,&nbsp;Amanda S. Sawyer,&nbsp;Rebecca Fogle,&nbsp;Amanda M. Holliday,&nbsp;Todd A. Schwartz,&nbsp;Ashley Leak Bryant","doi":"10.1016/j.jgo.2026.102976","DOIUrl":"10.1016/j.jgo.2026.102976","url":null,"abstract":"","PeriodicalId":15943,"journal":{"name":"Journal of geriatric oncology","volume":"17 6","pages":"Article 102976"},"PeriodicalIF":2.9,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148150127","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Quality of life and function in younger and older women treated for non-metastatic breast cancer: Three or more years post primary treatment","authors":"Karie Turley,&nbsp;Alexis C. Wardell,&nbsp;Allison M. Deal,&nbsp;Hyman B. Muss,&nbsp;Kirsten A. Nyrop","doi":"10.1016/j.jgo.2026.103032","DOIUrl":"10.1016/j.jgo.2026.103032","url":null,"abstract":"<div><h3>Introduction</h3><div>Advances in breast cancer treatments have reduced acute toxicities, but there can be lingering side effects that impact quality of life (QoL) and function years after treatment completion. Understanding these long-term sequelae in younger as compared older survivors under a variety of treatment scenarios may facilitate early symptom-moderating interventions.</div></div><div><h3>Materials and methods</h3><div>This is a single-arm observational study of women who are three or more years post primary treatment for early breast cancer (stage I-III). All study participants were recurrence-free and without active malignancies at the time of study recruitment when they completed a variety of patient-reported outcome (PRO) surveys. PROMIS-Global (Patient-Reported Outcomes Measurement Information System) Physical Function and PROMIS-Global Mental Health were the primary outcome variables.</div></div><div><h3>Results</h3><div>The cohort included 122 women under age 65 and 125 women age 65 or older at the time of follow-up. Younger survivors were more likely to have stage II-III disease (<em>p</em> = .05), undergo mastectomy (<em>p</em> &lt; .0001), and receive chemotherapy (<em>p</em> = .0009). Older survivors were more likely to receive radiation (<em>p</em> = .004) and endocrine therapy (<em>p</em> = .02). At follow-up, older survivors reported better mental health (<em>p</em> = .003), less anxiety (<em>p</em> = .007), less stress (<em>p</em> = .002), fewer endocrine symptoms (<em>p</em> ≤0.0001), and higher social/family well-being (<em>p</em> = .03). Older survivors also reported more severe neurotoxicity (<em>p</em> = .002) and worse aging-associated arthralgia (<em>p</em> = .05) compared to the younger women.</div></div><div><h3>Discussion</h3><div>Long-term QoL and function outcomes differ by age for early breast cancer survivors. The findings of this study highlight the need for age-specific monitoring and supportive care strategies to promote long-term quality of life and function in breast cancer survivors of all ages.</div></div>","PeriodicalId":15943,"journal":{"name":"Journal of geriatric oncology","volume":"17 6","pages":"Article 103032"},"PeriodicalIF":2.9,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148270593","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}